All In MedTech

FDA Clearance Tracker · P040024-S146

Restylane® Lyft with Lidocaine

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 23, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Dec 23, 2025

Approved

Time to decision

21 days

Received Dec 2, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P040024-S146
Device name
Restylane® Lyft with Lidocaine
Applicant
Q-Med AB
Applicant location
Uppsala
Received
Dec 2, 2025
Decided
Dec 23, 2025
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P040024

Device type

Device class
Class III

Every decision under product code LMH

FDA's approval statement

As written in FDA's record.

Approval for the postapproval study (PAS) protocol submitted to comply with the conditions of approval outlined in the approval order for P040024/S142.

Source documents

Other decisions for Q-Med AB

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.